Teprotumumab (teprotumumab-trbw; TEPEZZA™ - Horizon Therapeutics) is a 
monoclonal antibody insulin-like growth factor-I receptor (IGF-IR) antagonist 
developed for the treatment of thyroid eye disease (Graves 
ophthalmopathy/orbitopathy, thyroid-associated ophthalmopathy). Based on 
positive results from two multinational clinical trials teprotumumab was 
recently approved for this indication in the US. This article summarizes the 
milestones in the development of teprotumumab leading to this first approval for 
thyroid eye disease.